Skip to main content
Clinical Trials/NCT03524352
NCT03524352
Active, not recruiting
Phase 3

Prospective Multicenter Randomized Controlled Double-blind Label Study of the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis

Nantes University Hospital13 sites in 1 country42 target enrollmentMarch 12, 2020
ConditionsPouchitis

Overview

Phase
Phase 3
Intervention
fecal microbiota
Conditions
Pouchitis
Sponsor
Nantes University Hospital
Enrollment
42
Locations
13
Primary Endpoint
Number of days between the date of transplantation and the date of relapse according to physiological and endoscopic parameter (pochitis disease activity index)
Status
Active, not recruiting
Last Updated
2 months ago

Overview

Brief Summary

Ulcerative colitis (UC) is a chronic inflammatory digestive (IBD) disease medically treated with corticosteroids, aminosalicylates, immunomodulators, and biologics. Almost one third of UC patients will require surgical interventions because of fulminant colitis, dysplasia, cancer, or medical refractory diseases. Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the current standard surgical intervention. Anastomotic leak, pouch failure, pelvic sepsis, and pouch ischemia can occur after the procedure, but the most common long-term complication is pouchitis, an idiopathic inflammatory condition involving the ileal reservoir. Symptoms of pouchitis are increased stool frequency, urgency, incontinence, bloody stools, abdominal or pelvic discomfort, fatigue, malaise, and fever. The prevalence of pouchitis ranges from 23 to 46 %, with an annual incidence up to 40 %. Though the majority of initial cases of pouchitis are easily managed with a short course of antibiotics, in about 5 to 15 % of cases, inflammation of the pouch becomes chronic with very few treatments available.

Fecal microbiota transplantation (FMT) is a novel therapy to transfer normal intestinal flora from a healthy donor to a patient with a medical condition potentially caused by disrupted homeostasis of intestinal microbiota or dysbiosis. FMT has been widely used in refractory Clostridium difficile infection (CDI) and recently it has gained popularity for treatment of inflammatory bowel disease (IBD). Previous studies suggested that manipulating the composition of intestinal flora through antibiotics, probiotics, and prebiotic achieved significant results for treating acute episodes of UC-associated pouchitis. However, currently there is no established effective treatment for chronic antibiotic dependent pouchitis. Our project aims to evaluate the delay of relapse in chronic recurrent pouchitis after FMT versus sham transplantation.

Registry
clinicaltrials.gov
Start Date
March 12, 2020
End Date
May 12, 2028
Last Updated
2 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects must satisfy the following criteria to be enrolled in the study:
  • Male or female ≥ 18 years at the time of signing the informed consent form (ICF).
  • Subject must understand and voluntarily sign an ICF prior to conduct the study related assessments/procedure.
  • Willing and able to adhere to the study visit scheduled and other protocol requirements.
  • Subjects must have been operated with ileal pouch anal anastomosis (IPAA) with a duration of at least 6 month prior the screening visit.
  • Subject must have a diagnosis of recurrent pouchitis defined as at least 2 episodes in the last year or relapsing immediately after a reasonable response to antibiotherapy (the antifungal medication is allowed until the day before transplantation).
  • Subject must be in remission with a Pouchitis Disease Activity Index (PDAI) \< 7 at the screening
  • Subject must affiliation with social security system or beneficiary from such system
  • Female of childbearing potential must have a negative pregnancy test at screening and must agree to practice effective methods of contraception
  • NON-INCLUSION CRITERIA

Exclusion Criteria

  • Not provided

Arms & Interventions

fecal microbiota

Intervention: fecal microbiota

placebo

Intervention: Placebo

Outcomes

Primary Outcomes

Number of days between the date of transplantation and the date of relapse according to physiological and endoscopic parameter (pochitis disease activity index)

Time Frame: 106 weeks

Secondary Outcomes

  • Number of relapse rate according to pochitis disease activity index (physiological and endoscopic parameter)(52 weeks)
  • Number of days within the transplantation and the instauration of an antibiotherapy or alternative treatment(52 weeks)
  • Number of adverse events(104 weeks)
  • Number of fecal microbiota engraftment by 16S sequencing(8 weeks)
  • Number of relapse rate according to physiological and endoscopic parameter (pochitis disease activity index)(24 weeks)
  • Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)(52 weeks)
  • Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)(8 weeks)
  • Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)(24 weeks)
  • Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)(weeks -5)
  • Number of evolution of health-related to disability according to physiological and endoscopic parameter (pochitis disease activity index)(0 week)

Study Sites (13)

Loading locations...

Similar Trials